- freely available
Int. J. Mol. Sci. 2013, 14(1), 1684-1697; doi:10.3390/ijms14011684
Published: 15 January 2013
Abstract: Partitioning defective 3 (Par-3), a crucial component of partitioning-defective complex proteins, controls cell polarity and contributes to cell migration and cancer cell epithelial-to-mesenchymal transition. However, the clinical relevance of Par-3 in tumor progression and metastasis has not been well elucidated. In this study, we investigated the impact and association of Par-3 expression and clinical outcomes with hepatocellular carcinoma (HCC). We first confirmed that Par-3 was abundantly expressed in HCC cell lines by Western blot analysis. We used immunohistochemistry to analyze the association of Par-3 expression and clinicopathological characteristics in primary and subsequent metastatic tumors of patients with HCC. Par-3 was overexpressed in 47 of 111 (42.3%) primary tumors. Increased expression of Par-3 in primary tumors predicted an increased five-year cumulative incidence of extrahepatic metastasis. In addition, multivariate analysis revealed that Par-3 overexpression was an independent risk factor of extrahepatic metastasis. Increased Par-3 expression in primary tumors was associated with poor five-year overall survival rates and was an independent prognostic factor on Cox regression analysis. In conclusion, we show for the first time that increased Par-3 expression is associated with distant metastasis and poor survival rates in patients with HCC. Par-3 may be a novel prognostic biomarker and therapeutic target for HCC.
Hepatocellular carcinoma (HCC) is a serious malignancy and public health problem in endemic areas of hepatitis B or C virus infection, including Africa and Southeast Asia . Despite the aggressive surgical and non-surgical approaches used to treat and improve the outcome of HCC , local recurrence and distant metastasis remain major causes of treatment failure [3,4]. Investigating accurate prognostic biomarkers for early detection and prediction of recurrence and metastasis is critical for developing novel therapeutic strategies to improve outcome and survival for HCC patients.
Cell polarity is a fundamental property of all eukaryotic cells and is essential for the cell development of various organisms. Dysfunction of polarity leads to distinct diseases, including cancer progression . The partitioning defective (Par) complex comprises several proteins, including Par-3, Par-6 and atypical protein kinase C (aPKC), which regulate cell polarity and migration by regulating protein-protein interaction with several GTP-bound regulators [6–8]. In mammalian epithelial cells, the Par complex localizes to the apical junction region and plays a critical role in establishing apical-basal polarity and tight junctions [9–12]. Thus, the dynamic balance and regulation of the polarity-related proteins containing Par complex members are extremely important to modulate cancer cell migration and epithelial-to-mesenchymal transition. Dissolution of cell-cell junctions with loss of
Par-3 or Par-6 expression promotes cancer cell migration and invasion [8,13]. Conversely, amplification and increased expression of Par-6 and aPKC induced cell proliferation, more aggressive tumors and poor outcomes in breast cancer , ovarian cancer  and non-small-cell lung cancer . Par-3 expression and regulation are considered largely involved in cancer cell migration, and a few studies have suggested defective expression or amplified PARD3 gene in prostate cancer cells , esophageal squamous cell carcinoma , neoplastic retinal pigment epithelial cells  and HCC . Thus, Par-3 may play an important role in tumor development and cancer cell progression. However, the clinical significance of Par-3 expression in tumor metastasis and survival has never been elucidated. Therefore, in this study, we investigated Par-3 expression by immunohistochemistry in a cohort of patients with HCC. We evaluate the association of Par-3 expression with clinicopathological characteristics and survival rates. Par-3 overexpression was significantly associated with extrahepatic metastasis in HCC, and increased Par-3 expression was associated with worse overall survival with HCC. Our results suggest Par-3 as a potential biomarker and therapeutic target of HCC.
2.1. Protein Expression of Par-3 in HCC Cell Lines
Western blot analysis revealed Par-3 protein variants of 180, 150 and 100 kDa with differential expression in all HCC cell lines (Huh-7, HepG2, Hep3B, PLC-5 and SK-Hep-1) (Figure 1). Interestingly, the poorly-differentiated HCC cells, SK-Hep-1, expressed more multiple forms of Par-3 protein variants than other well-differentiated HCC cell lines.
2.2. Increased Par-3 Protein Expression in Primary and Metastatic HCC Tissues and Association with HCC Extrahepatic Metastasis
We examined the expression of Par-3 in paraffin-embedded primary HCC tumors with surrounding non-cancerous parenchyma from 111 patients and 31 matched extrahepatic metastatic tumors by immunohistochemical staining. Negative control slides were negatively unstained with Par-3 (Figure 2A). The expression of Par-3 was increased in 47 (42.3%) of 111 primary HCC tumors and not in non-cancerous cells adjacent to tumors (Figure 2B and Table 1). Moreover, Par-3 was overexpressed in 31 matched metastatic HCC specimens, as illustrated in brain (Figure 2C) and rectum (Figure 2D). Expression of Par-3 was not significantly related to most clinicopathological characteristics, but was associated with tumor multiplicity (p = 0.002), Alpha-fetoprotein level (p = 0.046) and subsequent extrahepatic metastasis (p = 0.037) (Table 1).
Multivariate analysis confirmed Par-3 expression as a predictor of distant HCC metastasis (p = 0.037) (Table 2). The cumulative rate of developing extrahepatic metastasis within five years with primary HCC was significantly higher with positive rather than negative Par-3 expression (40.2% ± 8.0% vs. 23.4% ± 6.0%, p = 0.047) (Figure 3). Furthermore, the expression of Par-3 was significantly increased in metastatic HCC samples than in their primary tumors (21 with increased Q-score > 2, and 10 with no difference in Q-score, p < 0.001). These observations suggest a strong association of Par-3 expression and extrahepatic metastasis of HCC.
2.3. Overexpression of Par-3 and HCC Patient Survival
After a mean follow-up of 52.0 ± 28.4 months after surgery, 27 patients (24.3%) remained free of HCC, 54 patients (48.6%) had died because of their disease and 30 patients (27.0%) were still alive with disease recurrence and/or distant metastasis. Survival analysis revealed a significantly better overall five-year survival with negative rather than positive Par-3 expression in primary HCC tumors (59.6% ± 6.3% vs. 41.7% ± 7.3%, p = 0.047) (Figure 4). The increased expression of Par-3 in primary tumors had no significant effect on progression-free survival in these patients (data not shown). In addition, Cox proportional-hazard regression models revealed that Par-3 overexpression was significantly associated with poor overall survival (hazard ratio 2.049, 95% confidence interval 1.082–3.884, p = 0.028), but not associated with progression-free survival (Table 3). Thus, overexpression of Par-3 in primary tumors is an important predictor of poor overall survival with HCC.
2.4. Correlation of Par-3 Expression with 14-3-3ɛ
To examine whether Par-3 expression is associated with 14-3-3ɛ (Par-5), we determined the 14-3-3ɛ expression by IHC analysis. Negative control slides were unstained with 14-3-3ɛ (Figure 5A). 14-3-3ɛ was significantly overexpressed in primary (Figure 5B) and metastatic HCC tumors, as representatively illustrated in brain and rectum (Figure 5C,D). Furthermore, overexpression of 14-3-3ɛ is significantly correlated with Par-3 in primary HCC tumors (p = 0.014) (Table 1).
Cell polarity is a basic and fundamental property of regular multiple cellular functions, including cancer cell migration and epithelial-to-mesenchymal transition. The Par-3/Par-6/aPKC complex is an essential regulator controlling cell polarity via interacting with various proteins. Human Par-3 (PARD3) is a single-copy gene consisting of 26 exons and localized in chromosome 10 . At least five PARD3 variants, derived from alternative splicing and polyadenylation, have been identified in a human liver cDNA library . Furthermore, multiple-splice PARD3 gene variants [21–23] and variants with three main molecular weights (180, 150 and 100 kDa) have been reported [18,24], although their specific role remains unclear. However, Par-3 expression in some tumors has been controversial. For instance, Par-3 protein or RNA expression was downregulated in esophageal squamous cell carcinoma and HCC [18,20], but PARD3 gene was found mutationally inactivated in prostate cancer cells . In contrast, gene amplification of aPKC-binding Par-3 protein was reported in transformed neoplastic retinal pigment epithelial cells . Par-3 was reported to localize and regulate epithelial tight junction assembly, which was promoted by epidermal growth factor receptor (EGFR)  and TGF-β  signaling. Moreover, overexpression of Par-3 suppresses contact-mediated inhibition of cell migration . Thus, Par-3 may be a “double-edged sword” in regulating cell migration and epithelial-mesenchymal transition (EMT), depending on the cell type or tissue. Also, the diverse role of Par-3 may be attributed to the distinct variants with different molecular weights, which may explain the Par-3 protein expression in the most migratory and poorly differentiated HCC cell line, SK-Hep-1, differing from that of the other cell lines (Figure 1). Nevertheless, little is known about whether and how Par-3 variants regulate cell polarity and contribute to cancer cell migration or EMT.
14-3-3 (also known as Par-5) potentially modulates cell polarity by directly binding with phosphorylated Par-3 [9,12,27]. We previously reported the expression of 14-3-3β, 14-3-3γ and 14-3-3ɛ isoforms increased in HCC, and their overexpression predicted a poor outcome with HCC [28–30]. Interestingly, we noted a significant association of Par-3 expression and 14-3-3, particularly 14-3-3ɛ, in primary and metastatic HCC (Figure 2vs.Figure 5, Table 1). Our immunoprecipitation findings also revealed that Par-3 directly interacts with 14-3-3ɛ to form a complex in HCC cells (unpublished data). Although the detailed mechanism of association or interaction between 14-3-3 proteins and Par-3 in tumor progression has not been elucidated, our results suggest that Par-3 may interact and collaborate with 14-3-3 to synergize HCC tumor progression. Further work is ongoing to uncover the role of Par-3/Par-6/aPKC complex interacting with 14-3-3 in regulating HCC development.
Results from this study indicate that increased Par-3 expression participates in promoting distant metastasis and reducing the survival rate of HCC patients. Elevated Par-3 expression in primary tumors is associated with risk of extrahepatic metastasis and poor overall survival with HCC. Thus, Par-3 alone or in combination with 14-3-3 proteins may be a biological marker identifying HCC patients at high risk of metastasis and poor survival. Therapeutic strategies or drugs aimed at Par-3 or 14-3-3 proteins might be developed for these patients.
4. Materials and Methods
4.1. Patients and Clinical Specimens
We retrospectively enrolled (from January 1999 to December 2001) and obtained tissue from 111 HCC patients who underwent surgery for tumor resection in Taichung Veterans General Hospital. The mean follow-up was 52.0 ± 28.4 months. In total, tissue from 31 patients (27.9%) showed metastasis 5 to 88 months after the surgery for primary HCC. The metastasis sites included bone, abdominal and chest wall, brain, mesentery, peritoneum, adrenal gland and retroperitoneum. The paraffin-embedded surgical specimens composed of the primary tumors with surrounding non-cancerous liver parenchyma and metastatic tumors underwent pathology examination. We examined pathological features, including Barcelona-Clinic Liver Cancer (BCLC)  staging and clinical outcomes. This study was approved by the Institutional Review Board of Taichung Veterans General Hospital.
4.2. Immunohistochemical Analysis
For immunohistochemistry analysis of Par-3 expression in paraffin-embedded tissues, we used an automatic immunostaining device and ultraView detection kit (Ventana XT Medical System, Tucson, AZ, USA) with a primary rabbit polyclonal antibody for Par-3 (1:100, Millipore, Clone 07–330, Temecula, CA, USA). Detection of 14-3-3ɛ expression was performed according to , described previously. A negative control was incubation without the primary antibody. The intensity of Par-3 and 14-3-3ɛ proteins staining were semiquantitatively scored by a Quick-score (Q-score) method based on intensity and heterogeneity [28–30,32–35]. Staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). For heterogeneity, the proportion of tumor cells positively stained with Par-3 was scored as 0 (0%), 1 (1%–25%), 2 (26%–50%), 3 (51%–75%) and 4 (76%–100%). The Q-score of a given tissue sample was the sum of intensity and heterogeneity scores and ranged from 0 to 7. The scoring of each sample was evaluated independently and blindly by 2 pathologists. A Q-score ≥2 was considered to be an overexpressed or positive expression of Par-3/14-3-3ɛ, and a Q-score <2 was considered a normal or negative expression of Par-3/14-3-3ɛ. Some rare cases with <5% weakly stained specimens were considered to be a negative expression.
4.3. Cell Culture and Western Blot Analysis
Huh-7, HepG2, Hep3B, PLC-5 and SK-Hep-1 human hepatoma cells were maintained in DMEM (Gibco, Gaithersburg, MD, USA), supplemented with 10% fetal bovine serum (FBS; Hyclone Thermo Fisher Scientific, Waltham, MA, USA), 100 units/mL penicillin and 100 units/mL streptomycin in a humidified incubator with 5% CO2 at 37 °C. Expression of Par-3 protein was determined by Western blot analysis. In brief, HCC cells were cultured to 90% confluence, harvested and lysed in ice-cold RIPA buffer (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10 mM EDTA; Millipore, Temecula, CA, USA) containing cocktail protease inhibitors (Roche, Indianapolis, IN, USA). Cell lysates were clarified by centrifugation at 15,000 rpm for 20 min at 4 °C. Protein concentration was determined by use of a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). In total, 20 μg protein from each sample was applied to a gradient SDS-PAGE gel and immunoblotted onto PVDF membranes, which were blocked for 1 h in PBST (0.1% Tween 20, 2.67 mM KCl, 1.47 mM KH2PO4, 137.93 mM NaCl, 8.1 mM Na2HPO4, pH 7.4) containing 5% nonfat dry milk, then incubated with primary antibody against Par-3 (Sigma-Aldrich, St. Louis, MO, USA) overnight, washed 3 times with PBST for 5 min, then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h. Protein levels were determined by use of enhanced chemiluminescence reagents.
4.4. Statistical Analysis
One-Way ANOVA was used to analyze differences for clinicopathological variables. Multivariate logistic regression was used to determine factors predicting extrahepatic metastasis. The Wilcoxon signed-rank test was used to analyze the differences between primary tumors and matched metastatic tissues by Par-3 staining density. Kaplan-Meier curves were plotted, and the log rank test was used to analyze time-related probabilities of metastasis, overall survival and progression-free survival. Cox proportional hazards regression models were used to evaluate the impact of prognostic factors on survival. p < 0.05 was considered statistically significant and p = 0.05 to 0.10 marginally significant.
In this study, we show for the first time that expression of Par-3 is increased and significantly associated with poor prognostic outcomes of HCC patients. To further investigate the molecular mechanism by which Par-3 is involved in regulating HCC tumors will benefit the implication of diagnosis or treatment for HCC. Thus, Par-3 alone or combined with 14-3-3ɛ or related interacting components may serve as the potential markers or therapeutic targets of HCC.
We thank the Comprehensive Cancer Center of Taichung Veterans General Hospital for providing information concerning the outcomes of patients. This work was supported by the National Science Council (NSC-98-2320-B-400-008-MY3), the National Health Research Institutes (NHRI-01A1-CSPP07-014), the Taichung Veterans General Hospital (TCVGH-1005801B) and the Department of Health (DOH100-TD-C-111-001) of Taiwan.
- Conflict of InterestThe authors declare no conflict of interest.
- Sherman, M. Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin. Liver Dis 2010, 30, 3–16, doi:10.1055/s-0030-1247128. 20175029
- Rampone, B.; Schiavone, B.; Martino, A.; Viviano, C.; Confuorto, G. Current management strategy of hepatocellular carcinoma. World J. Gastroenterol 2009, 15, 3210–3216, doi:10.3748/wjg.15.3210. 19598295
- Natsuizaka, M.; Omura, T.; Akaike, T.; Kuwata, Y.; Yamazaki, K.; Sato, T.; Karino, Y.; Toyota, J.; Suga, T.; Asaka, M. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J. Gastroenterol. Hepatol 2005, 20, 1781–1787, doi:10.1111/j.1440-1746.2005.03919.x. 16246200
- Hasegawa, K.; Kokudo, N. Surgical treatment of hepatocellular carcinoma. Surg. Today 2009, 39, 833–843, doi:10.1007/s00595-008-4024-z. 19784720
- Sawada, N.; Murata, M.; Kikuchi, K.; Osanai, M.; Tobioka, H.; Kojima, T.; Chiba, H. Tight junctions and human diseases. Med. Electron Microsc 2003, 36, 147–156, doi:10.1007/s00795-003-0219-y. 14505058
- Lin, D.; Edwards, A.S.; Fawcett, J.P.; Mbamalu, G.; Scott, J.D.; Pawson, T. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat. Cell Biol 2000, 2, 540–547, doi:10.1038/35019582. 10934475
- Ooshio, T.; Fujita, N.; Yamada, A.; Sato, T.; Kitagawa, Y.; Okamoto, R.; Nakata, S.; Miki, A.; Irie, K.; Takai, Y. Cooperative roles of Par-3 and afadin in the formation of adherens and tight junctions. J. Cell Sci 2007, 120, 2352–2365, doi:10.1242/jcs.03470. 17606991
- Chen, X.; Macara, I.G. Par-3 controls tight junction assembly through the Rac exchange factor Tiam1. Nat. Cell Biol 2005, 7, 262–269, doi:10.1038/ncb1226. 15723052
- Suzuki, A.; Ohno, S. The PAR-aPKC system: Lessons in polarity. J. Cell Sci 2006, 119, 979–987, doi:10.1242/jcs.02898. 16525119
- Humbert, P.O.; Dow, L.E.; Russell, S.M. The Scribble and Par complexes in polarity and migration: friends or foes? Trends Cell Biol 2006, 16, 622–630, doi:10.1016/j.tcb.2006.10.005. 17067797
- Hutterer, A.; Betschinger, J.; Petronczki, M.; Knoblich, J.A. Sequential roles of Cdc42, Par-6, aPKC, and Lgl in the establishment of epithelial polarity during Drosophila embryogenesis. Dev. Cell 2004, 6, 845–854, doi:10.1016/j.devcel.2004.05.003. 15177032
- Shin, K.; Fogg, V.C.; Margolis, B. Tight junctions and cell polarity. Annu. Rev. Cell Dev. Biol 2006, 22, 207–235, doi:10.1146/annurev.cellbio.22.010305.104219. 16771626
- Ozdamar, B.; Bose, R.; Barrios-Rodiles, M.; Wang, H.R.; Zhang, Y.; Wrana, J.L. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005, 307, 1603–1609, doi:10.1126/science.1105718. 15761148
- Nolan, M.E.; Aranda, V.; Lee, S.; Lakshmi, B.; Basu, S.; Allred, D.C.; Muthuswamy, S.K. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res 2008, 68, 8201–8209, doi:10.1158/0008-5472.CAN-07-6567. 18922891
- Eder, A.M.; Sui, X.; Rosen, D.G.; Nolden, L.K.; Cheng, K.W.; Lahad, J.P.; Kango-Singh, M.; Lu, K.H.; Warneke, C.L.; Atkinson, E.N.; et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 12519–12524, doi:10.1073/pnas.0505641102. 16116079
- Regala, R.P.; Weems, C.; Jamieson, L.; Copland, J.A.; Thompson, E.A.; Fields, A.P. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J. Biol. Chem 2005, 280, 31109–31115, doi:10.1074/jbc.M505402200. 15994303
- Kunnev, D.; Ivanov, I.; Ionov, Y. Par-3 partitioning defective 3 homolog (C. elegans) and androgen-induced prostate proliferative shutoff associated protein genes are mutationally inactivated in prostate cancer cells. BMC Cancer 2009, 9, 318, doi:10.1186/1471-2407-9-318. 19737411
- Zen, K.; Yasui, K.; Gen, Y.; Dohi, O.; Wakabayashi, N.; Mitsufuji, S.; Itoh, Y.; Zen, Y.; Nakanuma, Y.; Taniwaki, M.; et al. Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma. Oncogene 2009, 28, 2910–2918, doi:10.1038/onc.2009.148. 19503097
- Zitzelsberger, H.; Hieber, L.; Richter, H.; Unger, K.; Briscoe, C.V.; Peddie, C.; Riches, A. Gene amplification of atypical PKC-binding PARD3 in radiation-transformed neoplastic retinal pigment epithelial cell lines. Genes Chromosomes Cancer 2004, 40, 55–59, doi:10.1002/gcc.20024. 15034869
- Fang, C.M.; Xu, Y.H. Down-Regulated expression of atypical PKC-binding domain deleted asip isoforms in human hepatocellular carcinomas. Cell Res 2001, 11, 223–229, doi:10.1038/sj.cr.7290090. 11642408
- Gao, L.; Macara, I.G.; Joberty, G. Multiple splice variants of Par3 and of a novel related gene, Par3L, produce proteins with different binding properties. Gene 2002, 294, 99–107, doi:10.1016/S0378-1119(02)00681-9. 12234671
- Kohjima, M.; Noda, Y.; Takeya, R.; Saito, N.; Takeuchi, K.; Sumimoto, H. PAR3beta, a novel homologue of the cell polarity protein PAR3, localizes to tight junctions. Biochem. Biophys. Res. Commun 2002, 299, 641–646, doi:10.1016/S0006-291X(02)02698-0. 12459187
- Yoshii, T.; Mizuno, K.; Hirose, T.; Nakajima, A.; Sekihara, H.; Ohno, S. sPAR-3, a splicing variant of PAR-3, shows cellular localization and an expression pattern different from that of PAR-3 during enterocyte polarization. Am. J. Physiol. Gastrointest. Liver Physiol 2005, 288, G564–G570. 15358599
- Wang, Y.; Du, D.; Fang, L.; Yang, G.; Zhang, C.; Zeng, R.; Ullrich, A.; Lottspeich, F.; Chen, Z. Tyrosine phosphorylated Par3 regulates epithelial tight junction assembly promoted by EGFR signaling. EMBO J 2006, 25, 5058–5070, doi:10.1038/sj.emboj.7601384. 17053785
- Wang, X.; Nie, J.; Zhou, Q.; Liu, W.; Zhu, F.; Chen, W.; Mao, H.; Luo, N.; Dong, X.; Yu, X. Downregulation of Par-3 expression and disruption of Par complex integrity by TGF-beta during the process of epithelial to mesenchymal transition in rat proximal epithelial cells. Biochim. Biophys. Acta 2008, 1782, 51–59, doi:10.1016/j.bbadis.2007.11.002. 18070611
- Mishima, A.; Suzuki, A.; Enaka, M.; Hirose, T.; Mizuno, K.; Ohnishi, T.; Mohri, H.; Ishigatsubo, Y.; Ohno, S. Over-Expression of PAR-3 suppresses contact-mediated inhibition of cell migration in MDCK cells. Genes Cells 2002, 7, 581–596, doi:10.1046/j.1365-2443.2002.00540.x. 12059961
- Izaki, T.; Kamakura, S.; Kohjima, M.; Sumimoto, H. Phosphorylation-Dependent binding of 14-3-3 to Par3beta, a human Par3-related cell polarity protein. Biochem. Biophys. Res. Commun 2005, 329, 211–218, doi:10.1016/j.bbrc.2005.01.115. 15721295
- Ko, B.S.; Chang, T.C.; Hsu, C.; Chen, Y.C.; Shen, T.L.; Chen, S.C.; Wang, J.; Wu, K.K.; Jan, Y.J.; Liou, J.Y. Overexpression of 14-3-3epsilon predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology 2011, 58, 705–711, doi:10.1111/j.1365-2559.2011.03789.x. 21401702
- Ko, B.S.; Lai, I.R.; Chang, T.C.; Liu, T.A.; Chen, S.C.; Wang, J.; Jan, Y.J.; Liou, J.Y. Involvement of 14-3-3gamma overexpression in extrahepatic metastasis of hepatocellular carcinoma. Hum. Pathol 2011, 42, 129–135, doi:10.1016/j.humpath.2010.01.028. 20870266
- Liu, T.A.; Jan, Y.J.; Ko, B.S.; Chen, S.C.; Liang, S.M.; Hung, Y.L.; Hsu, C.; Shen, T.L.; Lee, Y.M.; Chen, P.F.; et al. Increased expression of 14-3-3beta promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am. J. Pathol 2011, 179, 2698–2708, doi:10.1016/j.ajpath.2011.08.010. 21967815
- Llovet, J.M.; Bru, C.; Bruix, J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis 1999, 19, 329–338, doi:10.1055/s-2007-1007122. 10518312
- Barnes, D.M.; Harris, W.H.; Smith, P.; Millis, R.R.; Rubens, R.D. Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br. J. Cancer 1996, 74, 1445–1451, doi:10.1038/bjc.1996.563. 8912543
- Chang, G.C.; Liu, K.J.; Hsieh, C.L.; Hu, T.S.; Charoenfuprasert, S.; Liu, H.K.; Luh, K.T.; Hsu, L.H.; Wu, C.W.; Ting, C.C.; et al. Identification of alpha-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes. Clin. Cancer Res 2006, 12, 5746–5754, doi:10.1158/1078-0432.CCR-06-0324. 17020980
- Jan, Y.J.; Ko, B.S.; Hsu, C.; Chang, T.C.; Chen, S.C.; Wang, J.; Liou, J.Y. Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Hum. Pathol 2009, 40, 1384–1390, doi:10.1016/j.humpath.2009.03.006. 19454363
- Lai, I.R.; Chu, P.Y.; Lin, H.S.; Liou, J.Y.; Jan, Y.J.; Lee, J.C.; Shen, T.L. Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am. J. Pathol 2010, 177, 1629–1637, doi:10.2353/ajpath.2010.100172. 20724588
|Table 1. Correlation between Par-3 expression in primary tumor and clinicopathological characteristics of hepatocellular carcinoma patients.|
|Parameters||Par-3 positivity (Q-score ≥ 2)% (n)||p-Value|
|Overall (n = 111)||42.3% (47)|
|≥60 years (n = 55)||40.0% (22)||NS|
|<60 years (n = 56)||44.6% (25)|
|Male (n = 84)||42.9% (36)||NS|
|Female (n = 27)||40.7% (11)|
|1 (n = 7)||42.9% (3)||NS|
|2 (n = 79)||41.8% (33)|
|3 (n = 25)||44.0% (11)|
|Types of surgery|
|Wedge resection (n = 39)||38.5% (15)||NS|
|Segmentectomy (n = 54)||38.9% (21)|
|Lobectomy (n = 18)||61.1% (11)|
|Free (n = 84)||42.9% (36)||NS|
|Involved (n = 27)||40.7% (11)|
|Not available (n = 5)|
|Early (stage A1 to A4) (n = 56)||44.6% (25)||NS|
|Intermediate (stage B) (n = 49)||40.8% (20)|
|Advanced (stage C) (n = 1)||100.0% (1)|
|≥5.0 cm (n = 36)||50.0% (18)||NS|
|<5.0 cm (n = 75)||38.7% (29)|
|Single (n = 86)||50.0% (43)||0.002 *|
|Multiple (n = 25)||16.0% (4)|
|Not available (n = 8)||NS|
|Yes (n = 60)||41.7% (25)|
|No (n = 43)||39.5% (17)|
|Yes (n = 48)||45.8% (22)||NS|
|No (n = 63)||39.7% (25)|
|Not available (n = 3)||NS|
|Yes (n = 56)||48.2% (27)|
|No (n = 52)||38.5% (20)|
|Not available (n = 7)|
|Hepatitis B (n = 56)||41.1% (23)||NS|
|Hepatitis C (n = 30)||43.3% (13)|
|Both (n = 15)||40.0% (6)|
|None (n = 3)||66.7% (2)|
|Not available (n = 12)||0.046 *|
|≥80 ng/mL (n = 36)||55.6% (20)|
|<80 ng/mL (n = 63)||34.9% (22)|
|Subsequent extrahepatic metastasis|
|Yes (n = 31)||58.1% (18)||0.037 *|
|No (n = 80)||36.3% (29)|
|Yes (n = 68)||51.5% (35)||0.014 *|
|No (n = 43)||27.9% (12)|
BCLC, Barcelona-Clinic Liver Cancer; NS, not significant; Q-score, Quick-score; SD, standard deviation;*p < 0.05.
|Table 2. Multivariate analysis for distant metastasis in hepatocellular carcinoma patients.|
|Histology grade (1 + 2 : 3)||NS|
|Presence of liver cirrhosis (No : Yes)||NS|
|Par-3 expression (negative : positive)||0.037 *|
|Bulky tumor (≥5.0 cm : <5.0 cm)||NS|
|Surgical margin (free : involved)||NS|
|Capsule formation (no : yes)||NS|
|Vascular thrombi (no : yes)||NS|
|BCLC staging (Stage A : B to C)||NS|
BCLC, Barcelona-Clinic Liver Cancer; NS, not significant.*p < 0.05.
|Table 3. Cox proportional hazard regression analysis for survival in hepatocellular carcinoma patients.|
|Variables||Overall survival||Progression-free survival|
|Hazard ratio (95% CI)||p-Value||Hazard ratio (95% CI)||p-Value|
|Par-3 expression (negative : positive)||2.049 (1.082–3.884)||0.028 *||1.486 (0.886–2.490)||0.133|
|Types of operation (wedge : wider resection)||0.719 (0.269–1.922)||0.510||0.756 (0.431–1.325)||0.329|
|Surgical margin (free : involved)||1.510 (0.763–2.988)||0.237||1.061 (0.580–1.941)||0.847|
|Capsular formation (no : yes)||1.357 (0.723–2.547)||0.342||1.543 (0.915–2.602)||0.104|
|Alpha-fetoprotein level (low : high)||1.824 (0.986–3.412)||0.059 #||1.757 (1.064–2.898)||0.028 *|
|Liver cirrhosis (no : yes)||1.294 (0.651–2.571)||0.463||1.059 (0.598–1.875)||0.845|
|BCLC stage (A : B and C)||1.861 (0.902–3.838)||0.093 #||1.555 (0.872–2.775)||0.135|
CI, confidence interval; BCLC, Barcelona-Clinic Liver Cancer; SE, standard error;*p < 0.05;#0.05 < p < 0.10.
© 2013 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).